Compare Deere & Company (DE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Summit Therapeutics Inc — how do they compare? Deere & Company trades at $616.53 (market cap $166.81B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Deere & Company is far larger — about 13.8× Summit Therapeutics Inc's market cap, and Deere & Company pays a 1.05% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DE | SMMT | |
|---|---|---|
Market Cap | $166.81B | $12.06B |
Sector | Industrials | Health |
52-Week High | $662.49 | $26.98 |
52-Week Low | $439.11 | $12.55 |
Enterprise Value | $221.63B | $11.39B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $620, up 1.76% over the past 24 hours, with a bullish technical signal and recent earnings beats. The stock shows strong profitability with a 10.33% net income margin and 18.51% ROE, though revenue declined to $44.67B in 2025. Analyst consensus is a Moderate Buy with a $669.79 price target, and the company maintains solid cash flow from operations of $7.46B.
Outlook remains positive due to consistent earnings outperformance and institutional support, but risks include cyclical agricultural demand pressures and high debt levels. The stock's valuation at a P/E of 35.01 may limit near-term upside if growth moderates.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
